Skip to main content
BEONE MEDICINES LTD. logo

BEONE MEDICINES LTD. — Investor Relations & Filings

Ticker · 688235 ISIN · CNE100005XT6 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 728 across all filing types
Latest filing 2023-04-21 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688235

About BEONE MEDICINES LTD.

https://beonemedicines.com/

BEONE MEDICINES LTD. is a biopharmaceutical company focused on the research, development, and commercialization of innovative therapeutic solutions, primarily in the field of oncology. The company specializes in the discovery of targeted small molecule drugs and biologics designed to address unmet medical needs in cancer treatment. Its research and development pipeline emphasizes precision medicine, utilizing advanced molecular biology and medicinal chemistry platforms to identify novel drug candidates. BEONE MEDICINES LTD. aims to improve patient outcomes by developing high-efficacy, low-toxicity therapies that target specific genetic drivers of disease. The company maintains a strong focus on clinical-stage development and strategic collaborations to advance its portfolio of next-generation medicines.

Recent filings

Filing Released Lang Actions
港股公告：审计委员会会议日期
Regulatory Filings Classification · 95% confidence The document is a short announcement (670 characters) from BeiGene, Ltd. stating that the Audit Committee meeting will be held on May 4, 2023, to review and approve the company's quarterly financial results for the period ending March 31, 2023. It does not contain the financial results themselves, only the notice of the meeting and the intention to approve and release the results. The document is an announcement about an upcoming audit committee meeting and financial results release, not the financial report itself. According to the 'Menu vs Meal' rule, this is not the report but an announcement related to it. Therefore, the appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement that does not fit other categories.
2023-04-21 Chinese
港股公告：审计委员会会议日期
Regulatory Filings Classification · 95% confidence The document is a short announcement (670 characters) from BeiGene, Ltd. regarding the date of an upcoming Audit Committee meeting scheduled for May 4, 2023, to review and approve quarterly financial results ending March 31, 2023. It does not contain any actual financial data or detailed report content but merely announces the meeting date and purpose. The document is not the financial report itself but a notice related to the audit committee meeting and financial results release. According to the 'Menu vs Meal' rule, such short announcements about upcoming reports or meetings are classified as Regulatory Filings (RNS).
2023-04-21 Chinese
百济神州有限公司自愿披露关于百泽安（替雷利珠单抗注射液）临床试验进展的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by BeiGene Ltd. regarding clinical trial progress of a drug (Tislelizumab injection). It contains no financial statements or detailed financial data. It is an announcement about clinical trial results and potential regulatory approval risks, not a financial report or earnings release. The document is relatively short (1788 characters) and serves as a public update on clinical progress and associated investment risks. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about clinical trial progress and risk disclosure without financial data or detailed report content.
2023-04-20 Chinese
百济神州有限公司章程
Governance Information Classification · 100% confidence The document is a detailed and lengthy text (15,000 characters) containing the amended and restated Articles of Association and Bye-laws of BeiGene, Ltd., a Cayman Islands company. It includes definitions, provisions on share capital, shareholder meetings, share transfers, and other corporate governance matters. The content is legal and governance-related, focusing on the company's internal rules, shareholder rights, board powers, and procedural regulations. There is no indication that this is an annual report, financial statement, earnings release, or any other financial report. It is not a short announcement or a certification but a full governance document. Therefore, the document fits the category of Governance Information (CGR).
2023-04-18 Chinese
百济神州有限公司关于召开2022年度业绩说明会的公告
Investor Presentation Classification · 90% confidence The document is an announcement about the scheduling and details of a 2022 annual performance explanation meeting (业绩说明会) to be held on April 26, 2023. It includes information on the meeting time, location, participants, and how investors can participate and ask questions. The document does not contain actual financial statements or detailed financial analysis but rather serves as a notice for an upcoming investor presentation event. The document length is short (1563 characters) and it is clearly an announcement of a meeting rather than the meeting materials or a report itself. Therefore, it fits best under the category of Investor Presentation (IP), as it relates to a detailed presentation for investors focusing on financials, strategy, and market position, even though the actual presentation will occur later.
2023-04-18 Chinese
百济神州有限公司关于建议修订公司组织章程大纲及细则的公告
AGM Information Classification · 95% confidence The document is an announcement from the board of directors of 百济神州有限公司 regarding proposed amendments to the company's Articles of Association (organizational charter) that require approval at the upcoming annual general meeting (AGM). It details the nature of the proposed changes to comply with Hong Kong Stock Exchange listing rules and corporate governance requirements. The document explicitly states that the amendments will be submitted for shareholder approval at the 2023 AGM and that the revised Articles will be disclosed on the Shanghai Stock Exchange website. The document is not the actual amended Articles or a full report but an announcement about the proposed amendments and the upcoming shareholder meeting where these will be voted on. It is also relatively short (3589 characters) and serves as a notice rather than a full report or presentation. Therefore, it fits best under the category of AGM Information (AGM-R), which covers presentations and materials shared during the AGM or related announcements about AGM agenda items.
2023-04-18 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.